Assembly Biosciences, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-21$38.50 RISE2026-03-30$26.64 PEAK2026-05-13$31.72 173d | -30.8% 129d | Missed | Missed | — | — | +19.1% 44d | Missed |
DROP2025-11-21$38.50 RISE2026-02-05$25.39 PEAK2026-02-23$29.95 94d | -34.1% 76d | Missed | Missed | — | — | +18.0% 18d | Missed |
DROP2025-08-22$26.93 RISE2025-09-16$20.55 PEAK2025-11-21$38.50 91d | -23.7% 25d | Missed | Missed | — | — | +87.3% 66d | Missed |
DROP2025-01-03$17.49 RISE2025-04-08$8.26 PEAK2025-07-07$18.56 185d | -52.8% 95d | Missed | Missed | — | — | +124.7% 90d | Missed |
DROP2024-09-20$19.43 RISE2024-12-18$13.51 PEAK2025-01-03$17.49 105d | -30.5% 89d | Missed | Missed | — | — | +29.5% 16d | Missed |
DROP2024-09-20$19.43 RISE2024-10-08$14.42 PEAK2024-10-15$18.52 25d | -25.8% 18d | Missed | Missed | — | — | +28.4% 7d | Missed |
DROP2024-06-24$15.70 RISE2024-08-07$12.62 PEAK2024-09-20$19.43 88d | -19.6% 44d | Missed | Missed | — | — | +54.0% 44d | Missed |
DROP2024-06-24$15.70 RISE2024-07-03$12.15 PEAK2024-09-20$19.43 88d | -22.6% 9d | Missed | Missed | — | — | +59.9% 79d | Missed |
DROP2024-04-11$15.06 RISE2024-04-30$12.47 PEAK2024-06-24$15.70 74d | -17.2% 19d | Missed | Missed | — | — | +25.9% 55d | Missed |
DROP2023-10-17$15.00 RISE2023-11-22$7.80 PEAK2024-01-30$12.48 105d | -48.0% 36d | Missed | Missed | — | — | +60.0% 69d | Missed |
DROP2023-10-17$15.00 RISE2023-11-21$7.80 PEAK2024-01-30$12.48 105d | -48.0% 35d | Missed | Missed | — | — | +60.0% 70d | Missed |
DROP2023-06-30$13.80 RISE2023-10-13$8.52 PEAK2023-10-17$15.00 109d | -38.3% 105d | Missed | Missed | — | — | +76.1% 4d | Missed |
DROP2023-06-30$13.80 RISE2023-08-25$10.68 PEAK2023-10-17$15.00 109d | -22.6% 56d | Missed | Missed | — | — | +40.4% 53d | Missed |
DROP2023-06-30$13.80 RISE2023-08-21$10.68 PEAK2023-10-17$15.00 109d | -22.6% 52d | Missed | Missed | — | — | +40.4% 57d | Missed |
DROP2023-01-31$20.88 RISE2023-05-30$11.40 PEAK2023-06-30$13.80 150d | -45.4% 119d | Missed | Missed | — | — | +21.1% 31d | Missed |
1–15 / 26 1 / 2 | |||||||
Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low. Oil up, gold and silver down. European and Asian markets closed higher.
Zoom Communications Inc shares rise after strong financial results and increased buyback authorization. Other big gainers include IMRX, INFQ, ASMB, IMAX, RGTI, HLIT, DELL, EL, GSIT, ELVR, and HPQ.
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the
"We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant unmet medical need despite existing PBC therapies, and in the case of PSC, no approved treatments," said Anuj Gaggar, MD,
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe
Assembly Biosciences, Inc. (ASMB) Bank of America Global Healthcare Conference 2026 May 13, 2026 7:35 PM EDTCompany ParticipantsAnuj Gaggar - Chief Medical...
Presentation Operator MessageOperator Here at the bank. And with me on the stage is Assembly Biosciences and Anuj Gaggar, Chief Medical Officer. Thank you so much for joining us.Presenter
Market forces rained on the parade of Assembly Biosciences, Inc. ( NASDAQ:ASMB ) shareholders today, when the analysts...
SOUTH SAN FRANCISCO, Calif., May 13, 2026 -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline...
We can readily understand why investors are attracted to unprofitable companies. Indeed, Assembly Biosciences...
SOUTH SAN FRANCISCO, Calif., May 11, 2026 -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Anuj...
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +26.03% and -10.73%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — Assembly Biosciences Inc. on Thursday reported a loss of $9.1 million in its first quarter. On a per-share basis, the South San...
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.71) by 23.94 percent. This is a 53.85 percent increase over losses of $(1.17) per share
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule...
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
2026-04-25. The following slide deck was published by Assembly Biosciences, Inc.
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation –
Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $39 to $43.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ASMB | +1.06% | -6.81% | -18.67% | +95.48% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -1.91% | -1.09% | -15.23% | +82.79% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 344.1K | $9.55M | 0.01% | Trimmed-42.7% | 2026-03-31 |
| StateStreet | passive | 56.7K | $1.57M | 0.00% | Added+7.0% | 2026-03-31 |
| Wellington | fundamental | 26.5K | $735.26K | 0.00% | New | 2026-03-31 |
| TwoSigma | quant | 20.6K | $570.26K | 0.00% | New | 2026-03-31 |
| RenTech | quant | 15.7K | $434.31K | 0.00% | Added+69.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -0.64 | -0.54 | +15.18% |
| 2026-03-19 | -0.85 | 2.48 | +392.91% |
| 2025-11-10 | -0.65 | -0.72 | -10.20% |
| 2025-08-06 | -1.73 | -1.33 | +23.12% |
| 2025-05-08 | -1.60 | -1.17 | +26.88% |
| 2025-03-20 | -1.75 | -1.57 | +10.29% |
| 2024-11-07 | -1.85 | -1.51 | +18.38% |
| 2024-08-08 | -2.23 | -1.98 | +11.21% |
| 2024-05-08 | -3.23 | -1.66 | +48.61% |
| 2024-03-28 | -3.18 | -1.74 | +45.28% |
| 2023-11-08 | -2.76 | -3.24 | -17.39% |
| 2023-08-09 | -3.18 | -3.84 | -20.75% |
| 2023-05-04 | -4.68 | -4.44 | +5.13% |
| 2023-03-22 | -5.76 | -5.52 | +4.17% |
| 2022-11-08 | -6.48 | -5.76 | +11.11% |
| 2022-08-09 | -5.76 | -6.12 | -6.25% |